Last reviewed · How we verify
Imfinzi
Imfinzi, marketed by University Medical Center Groningen, is an established treatment for extensive stage primary small cell carcinoma of the lung. Its key strength lies in its well-documented efficacy and safety profile, supported by robust clinical trial results. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Imfinzi |
|---|---|
| Also known as | durvalumab |
| Sponsor | University Medical Center Groningen |
| Target | Programmed cell death 1 ligand 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Extensive stage primary small cell carcinoma of lung
- Liver cell carcinoma
- Metastatic carcinoma to biliary tract
- Non-small cell lung cancer
- Small cell carcinoma of lung
- Transitional cell carcinoma
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imfinzi CI brief — competitive landscape report
- Imfinzi updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI